Similar content being viewed by others Introduction A progressive decline in skeletal muscle mass and strength, or sarcopenia, is increasingly recognized as a significant comorbidity in patients with type 2 diabetes mellitus (T2D) and obesity [1, 2]
Third, both the rates of, and factors associated with, treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors, indicating that patient-specific factors, rather than drug-specific factors (such as side-effects), are driving treatment discontinuation
Shastry, M., Jacob, S., Rugo, H
At Cymbiotika, we are dedicated to providing the tools and education you need to take control of your health
2013;31(6):S121S127